dc.contributor.author | Barkovskaya, Anna | |
dc.contributor.author | Seip, Kotryna | |
dc.contributor.author | Hilmarsdòttir, Bylgja | |
dc.contributor.author | Mælandsmo, Gunhild Mari | |
dc.contributor.author | Moestue, Siver Andreas | |
dc.contributor.author | Itkonen, Harri | |
dc.date.accessioned | 2019-05-22T11:08:36Z | |
dc.date.available | 2019-05-22T11:08:36Z | |
dc.date.issued | 2019-04-05 | |
dc.description.abstract | Post-translational modifcation of intracellular proteins with a single N-acetylglucosamine sugar
(O-GlcNAcylation) regulates signaling, proliferation, metabolism and protein stability. In breast
cancer, expression of the enzyme that catalyzes O-GlcNAcylation – O-GlcNAc-transferase (OGT), and
the extent of protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer
progression. Here we compare the signifcance of O-GlcNAcylation in a panel of breast cancer cells
of different phenotypes. We find a greater dependency on OGT among triple-negative breast cancer
(TNBC) cell lines, which respond to OGT inhibition by undergoing cell cycle arrest and apoptosis.
Searching for the cause of this response, we evaluate the changes in the proteome that occur after OGT
inhibition or knock-down, employing a reverse-phase protein array (RPPA). We identify transcriptional
repressor - hairy and enhancer of split-1 (HES1) - as a mediator of the OGT inhibition response in the
TNBC cells. Inhibition of OGT as well as the loss of HES1 results in potent cytotoxicity and apoptosis.
The study raises a possibility of using OGT inhibition to potentiate DNA damage in the TNBC cells. | en_US |
dc.description.sponsorship | National Institutes of Health
NCI | en_US |
dc.description | Source at <a href=https://doi.org/10.1038/s41598-019-42153-6>https://doi.org/10.1038/s41598-019-42153-6. </a> | en_US |
dc.identifier.citation | Barkovskaya, A., Seip, K., Hilmarsdòttir, B., Mælandsmo, G.M., Moestue, S.A. & Itkonen, H.M. (2019). O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes. <i>Scientific Reports</i>, 9:5670. https://doi.org/10.1038/s41598-019-42153-6 | en_US |
dc.identifier.cristinID | FRIDAID 1688438 | |
dc.identifier.doi | 10.1038/s41598-019-42153-6 | |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | https://hdl.handle.net/10037/15372 | |
dc.language.iso | eng | en_US |
dc.publisher | Nature Research | en_US |
dc.relation.journal | Scientific Reports | |
dc.relation.projectID | Kreftforeningen: 90393200 | en_US |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/FRIMEDBIO/239940/Norway/Cancer metabolism: From basic biochemistry to clinical opportunities// | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710 | en_US |
dc.title | O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |